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Abstract One of the most common features of exposure of
skin to ultraviolet (UV) light is the induction of inflamma-
tion, a contributor to tumorigenesis, which is characterized
by the synthesis of cytokines, growth factors and arach-
idonic acid metabolites, including the prostaglandins (PGs).
Studies on the role of the PGs in non-melanoma skin cancer
(NMSC) have shown that the cyclooxygenase-2 (COX-2)
isoform of the cyclooxygenases is responsible for the
majority of the pathological effects of PGE2. In mouse
skin models, COX-2 deficiency significantly protects
against chemical carcinogen- or UV-induced NMSC while
overexpression confers endogenous tumor promoting activ-
ity. Current studies are focused on identifying which of the
G protein-coupled EP receptors mediate the tumor promo-
tion/progression activities of PGE2 and the signaling path-
ways involved. As reviewed here, the EP1, EP2, and EP4
receptors, but not the EP3 receptor, contribute to NMSC
development, albeit through different signaling pathways
and with somewhat different outcomes. The signaling
pathways activated by the specific EP receptors are context
specific and likely depend on the level of PGE2 synthesis,
the differential levels of expression of the different EP
receptors, as well as the levels of expression of other
interacting receptors. Understanding the role and mecha-
nisms of action of the EP receptors potentially offers new
targets for the prevention or therapy of NMSCs.
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1 Prostaglandins and skin cancer
The development of cancer is a complex process during
which a normal cell undergoes a progressive series of
alterations resulting in the acquisition of an altered
proliferative capacity, invasiveness, and metastatic poten-
tial. For non-melanoma skin cancer (NMSC), these
changes are classically defined as occurring in stages: (a)
initiation, involving DNA damage leading to mutations,
(b) promotion, which involves proliferation and inflam-
mation, and (c) progression, involving additional genetic
mutations or structural genomic changes that result in
malignancy. The mouse skin model has been extensively
used to study molecular changes associated with the
dysregulated signaling that occurs in the different stages
of tumor development. This model is relevant to other
epithelial tissues and to humans and has been intensely
studied for this reason [1].
One of the most common features of tumor promotion
induced by chemicals or ultraviolet light (UV) in mouse
skin is the induction of inflammation, which is character-
ized by the synthesis of cytokines, growth factors, and
arachidonic acid metabolites as well as by the infiltration of
inflammatory cells such as macrophages and lymphocytes.
Of all the eicosanoids synthesized in the epidermis, the
prostaglandins (PGs) are the most abundant. The unstable
intermediates of the arachidonic acid-derived PGs are
synthesized by the cyclooxygenase (COX) enzymes,
COX-1 and COX-2, and further metabolized to PGE2,
PGF2α and PGD2 by specific synthases. COX-1 is
constitutively expressed in most tissues, and its PG
products, particularly PGE2, are involved in normal
physiological functions such as maintenance of the gastric
mucosa and regulation of renal blood flow. On the other
hand, COX-2 expression is undetectable in most unper-
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is highly inducible by various endogenous inflammatory
and mitogenic factors as well as exogenous agents such as
phorbol esters and UV. As observed in many other
epithelial tumors, COX-2 is constitutively upregulated in
human and murine NMSC, which is accompanied by a high
level of PG synthesis [1].
Both pharmacological and genetic approaches have been
used to demonstrate the contribution of the PGs to murine
skin cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs)
that target both COX-1 and COX-2, as well as selective
COX-2 inhibitors have been shown to prevent tumor
development elicited by either the chemical two-stage model
or by UV [2–4]. To unequivocally show that COX-2
expression and activity is critical for skin carcinogenesis,
COX-2 knockout mice were generated and shown to be
significantly protected from tumor development in either the
chemical two-stage model or UV model [5, 6].
To further assess the contribution of the PG products of
COX-2, transgenic mice overexpressing COX-2 were
generated using either the bovine keratin 5 (K5.COX-2
mice) or keratin 14 (K14.COX-2 mice) promoter [7, 8]. The
K14.COX-2 mice on the SKH-1 background developed
many more tumors in response to UV than their wild-type
counterparts [8]. Treatment of the K14.COX-2 transgenic
mice with the carcinogen dimethylbenz[a]anthracene
(DMBA) alone (i.e., in the absence of phorbol ester
promotion) also resulted in many more tumors than
occurred in wild-type mice, suggesting that chronically
high levels of PGs have intrinsic tumor promoting activity
[5]. Subsequent studies showed that application of PGE2 to
cultured murine keratinocytes or to murine skin caused the
activation of multiple signaling pathways resulting in
proliferation [9]. Interestingly, these are the same signaling
pathways activated by the phorbol ester tumor promoters,
suggesting that phorbol ester promotion occurs via its
enhancement of PGE2 synthesis [10].
Now that it has become well-established that induction
of COX-2 and its primary product, PGE2, are important
mediators of tumor promotion, attention has turned to the
downstream effectors of PGE2, as well as the other PGs.
The pharmacological classification of the PG receptors is
based on each receptor preferentially recognizing specific
PGs, e.g., PGD2 activates the D receptors, PGF2α the FP
receptors and PGE2 the EP receptors [11]. PGE2 binds and
activates four G-protein-coupled E receptors referred to as
EP1, EP2, E3, and EP4 [12, 13]. Like the other PG
receptors, the EP receptors have seven transmembrane
segments and each receptor is coupled to different Gα
subunits of the heterotrimeric G proteins. EP2 and EP4 are
linked to Gαs, commonly referred to as Gs. EP1 is linked
to Gq, while EP3 is couple to Gi. Ligand binding of the
different EP receptors leads to activation of distinct
downstream signaling pathways (Fig. 1). It is generally
accepted that the EP1 receptor activates phospholipase C
(PLC), which mediates activation of protein kinase C
(PKC) and elevation of cytosolic free calcium [14]. While
EP2 and EP4 both activate adenylate cyclase and increase
cAMP levels, EP4, but not EP2, is also coupled to the
phosphatidylinositol 3-kinase (PI3K) pathway [12]. EP3
differs from the other EP receptors in that multiple variants
can be generated by alternative splicing of the C-terminal
tail, with several variants inhibiting adenylate cyclase [13].
The signaling pathways that are activated are also depen-
dent in part on the level of PGE2 that is present, due to
differences in binding affinities between the receptors. The
EP1 receptor binds PGE2 with a Kd of 21 nM which is
higher than the 11.2 nM Kd for EP2 and the 2.9 nM Kd for
EP3 [15].
As will be discussed later, significant cross-talk can
occur between the canonical signaling pathways described
above and several additional pathways can be activated in
some cells. One of the most important of these is the recent
demonstration that the EP1, EP2, and EP4 receptors can
transactivate the epidermal growth factor receptor (EGFR);
EGFR-mediated signaling has been implicated in prolifer-
ation, invasion, resistance to apoptosis, angiogenesis, and
metastasis, all of which are associated with tumor develop-
ment [16]. In murine skin in particular, application of
diverse tumor promoters induce EGFR ligands, and both
EGFR and its ligands are constitutively upregulated in
papillomas and squamous cell carcinomas (SCCs) [17].
Fig. 1 Canonical signaling pathways activated by the EP receptors for
PGE2. EP1 activates phospholipase C (PLC), resulting in the
production of 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphos-
phate (IP3). DAG activates protein kinase C (PKC)w h i l eI P 3
mobilizes Ca
2+. EP2 activates adenylate cyclase (AC) which results
in elevated cAMP synthesis and protein kinase A (PKA) activation.
EP3 negatively regulates AC and thus cAMP levels are reduced. EP4
activates both the AC/cAMP pathway and the PI3K/AKT pathway.
The activation of these signaling pathways by the EP receptors in skin
results in biological changes that are associated with the promotion
and progression of NMSC
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networks that are activated by the EP receptors that has
hindered an understanding of how each of the EP receptors
elicit their multiple biological effects.
Each EP receptor subtype has distinct biochemical
properties and structures. The mouse EP1, EP2, EP3 (α
variant), and EP4 consists of 405, 362, 366, and 513 amino
acids, respectively. The amino acid identity among the EP
receptors is small, e.g., the identity of EP1 to EP2, EP3, and
EP4 is 30%, 33%, and 28%, respectively. Even EP2 and
EP4, which both activate adenylate cyclase, only have a
31% identity [12, 15]. The EP2 and EP3 receptors have the
most compact structures. EP1 has a long third loop as does
EP4, which also has the longest intracellular C-terminus
[12, 15]. The long cytoplasmic domain of EP4 interacts
with arrestins causing receptor internalization, something
that is unique to the EP4 receptor [18].
In general, the tissue distribution, cellular localization,
and level of expression are variable among tissues. EP3 and
EP4 are the most widely distributed, at least in mouse, with
their mRNAs expressed in almost all tissues. EP1 appears
to be restricted to several tissues, including kidney, lung,
stomach, colon, and skin. In many tissues, EP2 is the least
abundant of the receptors [19].
Expression of the EP genes is regulated by various
stimuli, both physiological and pathophysiological, result-
ing in variable levels of expression even in a given tissue.
Among the EP receptors, only EP4 expression is regulated
by a negative feedback loop [19]. Promoter analysis of the
EP2 and EP4 genes identified several consensus sequences
relevant to inflammatory stimuli inducing NF-IL6, NFκB,
and AP-2 in both genes, while the promoter region of EP2
also contains Sp1 and MyoD sequences, as well as a
putative glucocorticoid response element [20, 21].
In this review, the contribution of each of the EP
receptors to NMSC will be discussed. Because PGE2 is a
strong endogenous tumor promoter in murine skin, eluci-
dating the signaling pathways that are activated by the EP
receptors should improve our understanding of the molec-
ular basis for tumor promotion and also offer the possibility
of improved prevention/intervention in the development of
NMSC.
2 The EP1 receptor
Both human and mouse keratinocytes express all four EP
receptors which has made our understanding of how PGE2
functions as a tumor promoter difficult [22–24]. The EP1
and EP2 receptors are low affinity receptors, compared to
EP3 and EP4. While the high affinity receptors would be
expected to be activated at low levels of PGE2, such as
would occur in unperturbed skin, the low affinity receptors
are likely to be activated only in pathological conditions,
suggesting that its signaling is more likely to be activated
when COX-2 is induced and PGE2 synthesis is high,
conditions that are found early in skin tumor development.
Initial studies on the role of EP1 in skin focused on its
expression and localization. Konger et al. [25] were among
the first to show that EP1 is expressed in human epidermis
and that it occurs primarily in the cytoplasm of cells in the
granular layer. Both plasma membrane and perinuclear/
nuclear localization was observed in the basal layer and
stratum spinosum [25]. Lee et al. [26] and Tober et al. [27]
also reported that EP1 was found in the more suprabasal
layers of mouse skin, although Neumann et al. [23]
reported that EP1 expression occurred predominantly in
the basal compartment. The reason for the discrepancy
between laboratories is unknown but may be due to non-
specific antibody reactions.
Because the EP1 receptor is more likely to function under
conditions of stress or irritation, there has been greater interest
in understanding whether its expression levels change after
exposure of skin to UVor to chemical tumor promoters. Lee et
al. [26] showed that in UV-irradiated hyperplastic skin EP1
remained predominantly suprabasal but was strongly in-
creased. Tober et al. [27, 28] found no change in localization
after either acute or chronic UV exposure, but found an
increase in the mRNA for EP1 only after chronic, but not
acute, UV. Acute UV was shown, however, to upregulate
EP1 mRNA in cultured murine keratinocytes [29]. Our
laboratory showed that EP1 mRNA was elevated after both
acute and chronic UV irradiation, as well as after both single
and multiple topical treatments with the tumor promoter 12-
O-tetradecanoylphorbol 13-acetate (TPA) [30]. This upregu-
lation of EP1 after UVor TPA is significant because both UV
and TPA cause an upregulation of COX-2 with a concomitant
increase in PGE2 [1]. The increase in PGE2 a n di nE P 1
suggests that this receptor may function as a “stress” receptor.
EP1 receptor expression in murine and human NMSCs
has also been investigated. In UV-induced papillomas
and SCCs in mice, EP1 was highly expressed as measured
by immunohistochemistry. Interestingly, EP1 was not
expressed in murine basal cell carcinomas (BCCs). Similar
observations were made for human actinic keratosis, SCCs
and BCCs [26]. Konger et al. [31] also reported that well-
differentiated SCC's had significantly greater membrane
staining while BCC's and spindle cell carcinomas had
notably reduced membrane staining. At the mRNA level,
EP1 was found to be upregulated significantly in murine
papillomas and SCCs generated either with a UV or
initiation-promotion protocol by several laboratories in-
cluding our own [27, 30].
A likely role for the EP1 receptor in skin carcinogenesis
was suggested by the reports that EP1 null mice or use of
selective EP1 antagonists resulted in reduced colon and
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investigated the effects of topical application of the EP1
antagonist ONO-8713 on UV-induced cutaneous inflam-
mation and tumor development. Using skin thickness
(vascular permeability) and neutrophil infiltration as meas-
ures of an inflammatory response, they found that the EP1
antagonist reduced these parameters as well as the level of
PGE2. More significantly, in a UV carcinogenesis experi-
ment, the EP1 antagonist reduced tumor multiplicity by
∼50% relative to wild-type controls. In the same experi-
ment, topical application of the selective COX-2 inhibitor
celecoxib reduced tumor multiplicity somewhat more,
∼60%, but the combination of ONO-8713 and celecoxib
had no greater effect [4]. These data offer insight into the
biochemical events needed for, or contributing to, skin
carcinogenesis. Celecoxib is a potent COX-2 inhibitor but
does not completely stop synthesis of PGs [2, 4], likely due
to continued low level synthesis of PGs from COX-1. The
Tober et al. [4] observations also suggest that EP1 is
responsible for a large part of the tumor promoting activity
of PGE2. The remainder of the activity is likely due to
activation of the other EP receptors or possibly one or more
of the peroxisome proliferator-activating receptors, which
are known to be activated by eicosanoids [35].
To more definitively determine the contribution of the
EP1 receptor to skin tumor development, our laboratory
generated transgenic mice (BK5.EP1) that overexpress
EP1, under control of a bovine keratin 5 (BK5) promoter,
in the basal layer of murine epidermis [30]. Skins of these
mice were histologically indistinguishable from wild-type
mice and had similar levels of epidermal cell proliferation
after topical treatment with TPA. Surprisingly, using a
carcinogenesis protocol employing the carcinogen DMBA
and the tumor promoter TPA, the BK5.EP1 mice produced
significantly fewer tumors compared to wild-type mice.
PKC, the receptor for TPA that mediates its tumor
promoting activity [36], was found to be downregulated
in the BK5.EP1 epidermis, which likely explains the
refractoriness to TPA promotion [30]. However, even
though tumor multiplicity was reduced in the transgenic
mice, the percentage of tumors that were SCC were very
high compared to wild-type mice, i.e., they had an
approximately eightfold-higher papilloma to carcinoma
conversion rate [37]. To circumvent the potential problem
of PKC downregulation, another tumor promoter, anthralin,
which generates free radicals and does not interact with
PKC [38] was used in place of TPA. With this protocol,
tumor multiplicity and tumor incidence were increased
twofold in BK5.EP1 mice compared to wild type. More
significantly, however, was the observation that the trans-
genic mice had a ninefold increase in SCCs. Overall, these
tumor experiments indicate that the effect of EP1 over-
expression is protocol- and agent-dependent with regard to
papilloma development, but consistently contributed to
progression of papillomas to SCCs [30].
In a recent study, our laboratory found that a single topical
application of DMBA orbenzo[a]pyrene alone was sufficient
to elicit SCCs in the BK5.EP1 transgenic mice, but not in
wild-type mice. This difference was not due to alterations in
carcinogen metabolism, DNA adduct formation, or Ras
activity. Because PGE2 signaling has been shown to be
important in maintaining hematopoietic stem cell homeosta-
sis, the effects of EP1 receptor overexpression on keratino-
cyte stem cell numbers was investigated as a possible
mechanism for the dramatic increase in SCC's seen in the
BK5.EP1 model. Using CD34 and α6 integrin as markers
[39], no differences were observed between the transgenics
and wild-type mice [37]. However, EP1 transgene over-
expression caused COX-2 expression in the epidermis,
which is not normally seen in wild-type mice. To determine
the significance of this upregulated COX-2, the selective
COX-2 inhibitor celecoxib was administered in the diet
before DMBA application. While the DMBA-treated BK5.
EP1 control mice had significant hyperplasia and inflamma-
tory cell infiltration for at least 2 weeks, the celecoxib-fed
mice had relatively normal skin architecture and very few
inflammatory cells, and remained normal for the duration of
the experiment. To verify that this was not an off-target effect
of celecoxib, BK5.EP1 mice were crossed with COX-2 null
mice. Loss of one allele of COX-2 reduced tumor develop-
ment by 50% while loss of both alleles completely prevented
tumor development, demonstrating a requirement for the
PGs generated from COX-2 in the development of skin
tumors in the BK5.EP1 model [37].
It is clear from the above tumor studies employing
genetic or pharmacological approaches to up- or down-
regulate EP1 activity, that the EP1 receptor plays a major
role in the pro-tumorigenic action of PGE2. What remains
to be determined is the mechanisms and signaling pathways
by which this occurs. Konger et al. [40] showed that in
human keratinocytes EP1 activation is coupled to intracel-
lular calcium mobilization, as is found in many other cell
types [12]. They further demonstrated that EP1 expression,
particularly when localized to the membrane, is associated
with keratinocyte differentiation, which is known to be
induced by calcium mobilization [31] and is usually
associated with decreased tumorigenesis. In rat osteoblasts,
the EP1 receptor was shown to signal through a PLC/PKC/
c-Src signaling pathway [14]. PLC activation hydrolyzes
phosphatidyl inositol 4,5-bisphosphate into two second
messengers, inositol 1,4,5-trisphosphate, which triggers
calcium mobilization, and diacyglycerol (DAG) which
activates PKC [41]. It is likely that this signaling pathway
(Fig. 2) is operative in keratinocytes based on the
observations that activation of EP1 causes calcium mobi-
lization [40] and PKC is downregulated in the epidermis of
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occurs as a result of its activation, which is also something
the tumor promoter TPA causes, overexpression of EP1
may lead to autonomous tumor promotion [37]. In support
of this, Thompson et al. [42] reported that malignant murine
keratinocytes are stimulated by PGE2 to proliferate and that
this was mediated by the EP1 receptor.
In summary, the currently available data suggest that the
EP1 receptor plays a role not only in keratinocyte
differentiation, but more importantly it contributes signifi-
cantly to the development of NMSC. The extent to which
these observations extend to other tissues is likely to be
context and tissue specific. EP1 receptor deficiency
significantly reduced azoxymethane-induced colon cancer
in mice, suggesting that the EP1 receptor is likely to be pro-
tumorigenic in self-renewing epithelium such the epidermis
and gastrointestinal tract [32]. However, reduced EP1
expression increased the metastatic capacity of breast
cancer cells [43], suggesting that EP1 may have anti-
tumorigenic activity in certain contexts. Additional studies
are needed to elucidate the mechanisms by which the EP1
receptor influences these neoplastic processes.
3 The EP2 receptor
Like the EP1 receptor, the EP2 receptor is a low affinity
receptor and thus likely to be more important during
disturbances of skin homeostasis and/or integrity. Like
EP1, EP2 has also been shown to be localized to both the
perinuclear and outer membrane of normal human kerati-
nocytes in the basal and spinous layer. Unlike EP1,
however, little EP2 was observed in the superficial stratum
spinosum. The localization of EP2 (and EP1) in the
perinuclear membrane is of interest because COX-1 and
COX-2 localize to the nuclear membrane as well as the
endoplasmic reticulum, suggesting possible nuclear second
messenger signaling [25]. In mouse, the EP2 receptor was
found by immunohistochemistry both on the plasma
membrane and within the cytoplasm [27]. Patchy expres-
sion throughout the epidermis has also been reported [26].
However, because mice have a very thin epidermis that
lacks the defined granulosa and spinous layers of differen-
tiated human epidermis, it is difficult to assess whether the
decreased expression in the more differentiated human
keratinocytes also occurs in mouse.
Investigations in our laboratory showed that the level of
expression of the EP2 receptor can be modulated by tumor
promoting stimuli [44]. Topical application of the phorbol
ester TPA upregulated EP2 mRNA more than fivefold
following single or repeated applications [44]. We also
found that exposure of mouse skin to UV, either once or
repeatedly, also significantly elevated EP2 (unpublished
data), although another study reported that EP2 was
elevated only after chronic UV exposure, not after an acute
exposure [27].
The expression levels and patterns of the EP2 receptor
have also been examined in skin tumors resulting from
either UV or chemical carcinogenesis protocols. In benign
papillomas and SCCs of SKH-1 mice subjected to UV
irradiation, EP2 immunohistochemical staining remained
patchy. Interestingly, no expression of EP2 was observed in
BCCs [26]. In a study by Tober et al. [27] on UV-induced
tumors, EP2 protein was found only in the highly
differentiated cells surrounding keratin pearls. While we
found that UV significantly elevated EP2 mRNA levels in
both papillomas and SCCs of SKH-1 mice (unpublished
data), this was not observed in another study [27]. In
papillomas and SCC from chemical initiation–promotion
protocols, EP2 mRNA was upregulated at least 15-fold in
FVB mice. This was confirmed at the protein level as well
[44]. Another study, using papillomas from NMRI mice,
also reported an elevation in EP2 mRNA expression [23].
Thus the majority of the studies indicate that the EP2
receptor mRNA levels are elevated in squamous carcino-
mas, compared to uninvolved skin.
The increased expression of EP2 following tumor
promoter treatment and in skin tumors resulting from these
treatments led to the question of whether EP2 contributes to
the development and/or progression of tumors. To address
this, we subjected mice that were null for the EP2 receptor
Fig. 2 EP1 signaling in keratinocytes. Ligand activation of the EP1
receptor causes conformation changes resulting in activation of the
heterotrimeric G protein, Gq. Activation causes release of GDP from
the Gα subunit and the binding of GTP, which is associated with
release of Gβγ and activation of phospholipase C beta (PLCβ).
Activated PLCβ hydrolyzes phosphatidyl inositol 4,5-bisphosphate to
1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3
raises cytoplasmic Ca
2+ levels via movement from endoplasmic
reticulum stores, leading to activation of calcium signaling pathways.
DAG activates protein kinase C (PKC), which subsequently activates
the MAPK pathway via Raf-1 activation. PKC can also be activated
by the phorbol ester tumor promoters; chronic activation of EP1 may
confer tumor promoting/progression activity through PKC
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null mice had significantly fewer tumors (∼50%) and
reduced tumor incidence compared to their wild-type
counterparts. Tumor size distribution for the EP2 knockout
mice was similar for small to medium size tumors (<5 mm
diameters), however, the EP2 null mice produced fewer
large tumors, compared to wild-type mice. Significantly, no
SCCs were produced in the EP null mice whereas 20% of
the wild-type mice developed SCCs [24].
To further understand the contribution of EP2 to skin
tumor development, a number of parameters associated
with cancer were assessed in the EP2 null mice. In
untreated EP2 null mice, the extent of basal cell prolifer-
ation was slightly reduced compared to wild-type mice.
Following a single treatment with TPA at a dose known to
cause marked proliferation and hyperplasia, there was a
significant reduction in the EP2 null mice. This suggested
that the EP2 receptor may play an important role in
mediating TPA-induced proliferation and that the increased
PGE2 synthesis elicited by TPA may be responsible for this.
While cultures of primary keratinocytes from wild-type
mice showed a large proliferative response to exogenous
PGE2, the EP2 null keratinocytes had a reduced prolifera-
tive response. This suggested that PGE2 mediates an
autonomous proliferative response in keratinocytes, i.e.,
PGE2 from dermal stromal cells are not necessary [24].
This study also corroborated an early study showing that
the EP2/EP4 receptors mediate PGE2-induced proliferation
in primary human keratinocytes [45].
The effect of EP2 deletion on TPA-induced inflamma-
tion and angiogenesis were also assessed. There was a
significant reduction in the infiltration of macrophages into
the dermis of EP2 null mice, as well as markedly reduced
expression of interleukin-1α in the epidermis and a
significantly reduced angiogenesis. Additionally, deficiency
in EP2 receptor expression reduced the level of cAMP
elicited by topical application of PGE2 to basal levels [24].
Use of EP2 null mice, on the SKH-1 background, in UV
carcinogenesis experiments produced different results than
observed in the two-stage model described above. Broux-
hon et al. [46] reported that acute low-dose UV exposure
produced a markedly reduced proliferative response com-
pared to wild-type mice, while with higher doses the
proliferative response was the same, although the hypertro-
phy response remained depressed. The EP2 null SKH-1
mice produced 50% fewer tumors than the wild-type mice,
similar to the two-stage chemical protocol, but their tumors
were larger in size, with a more aggressive phenotype as
indicated by their poor differentiation. These less kerati-
nized tumors were also more deeply invasive than the well-
differentiated tumors. To understand how deletion of the
EP2 receptors could lead to a more invasive phenotype,
enzymes involved in matrix remodeling were analyzed.
Matrix metalloproteinase (MMP)-2 and MMP-9 activity
were dramatically increased in UV-irradiated EP2 null
SKH-1 mice, which likely contributed to the enhanced
SCC invasion [46].
Although the number of skin tumors was reduced in EP2
null mice in both the two-stage and UV carcinogenesis
protocols, the issue that remains unanswered is why a
decreased tumor aggressiveness was seen in the two-stage
chemical protocol while increased aggressiveness was seen
in the UV study. There are several possibilities that will
require additional studies to resolve this issue. First, the
types of mutations induced by the two protocols are
different. The carcinogen DMBA causes mutations in the
H-ras gene [10], while UV primarily causes mutations in
the p53 gene [47]. The interplay of these mutations with
PGE2 signaling may be different. Second, the strain
background of the mice used in these two studies is
different. The SKH-1 mice carry a mutation in the hairless
gene, which has been shown to be a tumor suppressor gene
that is responsible for the UV susceptibility of these mice
[48]. The relationship of this mutation to chemical
carcinogenesis or to human NMSC is not known. Thus,
targeting the EP2 receptor for prevention of skin cancer
may be premature and clearly requires additional study.
While the EP2 knockout study suggests that EP2
expression is needed for a full tumorigenic response, it
was unknown whether increasing EP2 above normal levels
would enhance tumor development. To address this
question, we generated EP2 transgenic mice in which the
EP2 transgene was under the control of the BK5 promoter
(BK5.EP2 mice). The EP2 receptor was primarily
expressed in the basal layer of the epidermis where the
keratin 5 promoter is most active. When subjected to a two-
stage carcinogenesis protocol, the BK5.EP2 mice devel-
oped more papillomas than wild-type mice. More notable,
however, was the marked increase (threefold) in the number
of SCCs in the BK5.EP2 mice. Additionally, the BK5.EP2
mice produced much larger tumors than their wild-type
counterparts. In both papillomas and SCC from the EP2
transgenic mice, the level of EP2 expression was higher
than that in wild-type tumors, likely due to both endoge-
nous EP2 and transgene EP2 expression. This was
interpreted as suggesting that the EP2 receptor significantly
contributes to the development of, and perhaps more
importantly, to the progression of benign to malignant
tumors. As was expected, the epidermis of BK5.EP2 mice
produced a greater proliferative and inflammatory response
to TPA. Overexpression of the EP2 receptor also caused an
increase in angiogenesis, even in untreated mice, where
macroscopic inspection of the dermis showed an increase in
the number and size of the vessels. As opposed to the
reduction in cAMP seen in EP2 receptor knockout mice,
EP2 receptor overexpression significantly elevated PGE2-
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type mice, which is in agreement with a model in which
PGE2 elevates cAMP levels through EP2 activation, which
in turn induces genes involved in proliferation, inflamma-
tion, and angiogenesis [44, 49].
A proliferative response to EP2 activation is not
restricted to murine keratinocytes. Konger et al. [45]
showed that proliferation of primary adult human keratino-
cytes is increased following activation of EP2 and
subsequent production of cAMP. They later showed that
in immortalized human keratinocytes (HaCaT cells) loss of
EP2 receptor expression was associated with increased
invasiveness and decreased expression of paxillin, a
component of focal adhesion complexes [50]. Several
possible explanations were offered for this observation,
including defects in post-translational modification, much
reduced expression of COX-2 and reduced synthesis of
PGE2. As the authors suggested, the normally reduced PG
production may contribute to the normally non-invasive
phenotype of HaCaT cells [50].
Given the generally pro-tumorigenic function of the EP2
receptor, there is considerable interest in elucidating the
mechanisms and signaling pathways involved. Although
both EP2 and EP4 activate adenylate cyclase, Fujino et al.
[51] reported that the stimulation of cAMP in EP4-
expressing cells is significantly less than in EP2-expressing
cells at equal levels of receptor expression. Additionally, EP4
receptors, but not EP2, undergo rapid agonist-induced
desensitization and internalization. EP4, but not EP2, was
alsofoundtoactivatethe PI3K/AKTpathway.Ina later study,
Fujino et al. [52]r e p o r t e dt h a tP G E 2 stimulation of cells
expressing either the EP2 or EP4 receptor results in
phosphorylation of CREB
ser133. However, inhibition of
PKA reduced this phosphorylation in EP2 expressing cells,
but not in EP4 expressing cells. They provided evidence that
activation of the EP4 receptor, but not EP2, results in
activation of a PI3K pathway that inhibits the activity of
PKA. It was concluded that although both EP2 and EP4
cause phosphorylation/activation of CREB, they do so
through different signaling mechanisms [52]. On the other
hand, Castellone et al. [53] reported that EP2 receptor
stimulation of proliferation in colon cancer cells involved
both the PI3K/AKT and axin/β-catenin pathways. They
showed that the free G protein β/γ subunit activated PI3K/
AKTwhile the Gαs subunit associated with the “regulator of
Gp r o t e i n ” domain of axin, leading to activation of β-catenin
and proliferation of DLD-1 cells that carry a mutation in the
APC gene. Contrary to expectations, PKA activation was not
involved in the EP2-mediated proliferation [53]. Thus, it
appears that the signaling pathways activated by the EP2
receptor that lead to proliferation are likely to be cell-type
and/or context specific with regard to other signaling
alterations or mutations.
With regard to keratinocytes, the Langenbach laboratory
hasbeenparticularlyinterestedinunderstandinghowCOX-2-
generated PGs protect the skin from UV-induced apoptosis
and the relationship between the reduced apoptosis and tumor
development [54–56]. They compared the protein levels of
all the EP receptors following UV exposure of COX-2 null
and wild-type mice and found that although EP1, EP2, and
EP4 were induced in wild-type mice, EP2 and EP4 levels
were 50% lower in the COX-2 null mice. The levels of
activated PKA and AKT were also reduced in the COX-2
nulls, as were the phosphorylated forms of the anti-apoptotic
protein Bad, pBad
ser136 and pBad
ser155, which are down-
stream products of activated AKT and PKA, respectively
[55]. These findings suggested that both EP2 and EP4 are
responsible for the anti-apoptotic effects of PGE2 in the
setting of UV-induced COX-2. To confirm this suggestion,
COX-2 null mice were exposed to UV to induce apoptosis,
followed by topical application of EP2 and EP4 agonists,
each of which reduced epidermal apoptosis by 50% in the
COX-2 null mice. It was proposed that the remaining
apoptosis was independent of EP2/EP4 and likely occurred
through a PG-independent pathway [56].
Our laboratory has also been interested in a possible
feedback relationship between COX-2, PGE2, and EP2.
Maldve and Fischer [57] showed that in primary cultures of
murine keratinocytes, PGE2 could induce COX-2. Subse-
quently, we reported that EP2 null mice had a reduced
induction of COX-2 following TPA treatment [49]. Con-
versely, primary keratinocyte cultures from EP2 transgenic
mice had increased COX-2 expression after either TPA or
PGE2 treatment which was blocked by an adenylate cyclase
inhibitor. PGE2 treatment also caused greater phosphoryla-
tion of CREB in keratinocytes from EP2 transgenic mice,
compared to wild-type mice; phosphorylation was reduced
when a PKA inhibitor was included. Conversely, there was
no CREB phosphorylation in EP2 null mice following
PGE2 treatment and this correlated with a lack of a
proliferative response to PGE2 [49]. These events are
indicative of a positive feedback loop between COX-2
and EP2 and it has been suggested that this could result in
the continuous overexpression of COX-2 that is observed in
many epithelial tumors [56].
To further elucidate the contribution of EP2 to papilloma
development in the mouse skin initiation-promotion model,
Langenbach's laboratory looked at the effects of inhibiting
PKA and EGFR, each of which reduced tumor multiplicity
by ∼50% [58]. To assess EP2's contributions to the
activation of these pathways, mice were treated with an
EP2 agonist concomitantly with the NSAID indomethacin
to inhibit TPA induction of endogenous PGE2 synthesis.
The agonist restored tumor development that was inhibited
by indomethacin and increased cAMP and PKA activity.
The agonist also increased c-Src and EGFR activation [58].
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than a linear cAMP-PKA-pCREB pathway, which was
described earlier. Chun et al. [58] in fact found that EP2
could be immunoprecipitated as a complex with β-arrestin1
and p-Src
Tyr416. Thus, the contribution of EP2 to skin tumor
development is likely via activation of both the cAMP/PKA
and EGFR pathways. What remains unclear, however, is
the mechanism by which the EP2 receptor activates EGFR.
While c-Src mediated activation has been reported in
murine keratinocytes [58], a study on human epidermoid
A431 and SCC-9 cells showed that EP2-mediated EGFR
transactivation can also occur via PKA activation [59],
again indicating cell or context specificity.
The Langenbach lab has also explored the possibility
that the β-arrestin1-Src complex contributes to EP2-
mediated signaling in murine keratinocytes [58]. The
EP2 agonist butaprost induced complex formation with
subsequent c-Src and EGFR activation, which was
dependent on the presence of β-arrestin1 (Fig. 3). Butap-
rost also induced the activation of AKT, ERK1/2, and
STAT3, all of which were inhibited by β-arrestin defi-
ciency or EGFR inhibition. Butaprost also increased PKA
activation leading to phosphorylation of CREB, as
expected, but inhibition of PKA did not affect butaprost-
induced activation of EGFR. This observation, plus the
finding that β-arrestin1 deficiency did not affect
butaprost-induced PKA activation, indicated that there
are independent EP2-mediated signaling pathways, both of
which contribute to murine keratinocyte proliferation [58].
To further investigate the mechanism by which EP2
mediates keratinocyte survival, Chun and Langenbach [60]
explored the possible role of survivin, a regulator of cell
survival. They reported that exposure to UV upregulated
survivin and pSTAT3, a transcription factor that regulates
survivin expression. Mice deficient in either COX-2 or EP2
had a reduced ability to increase the expression of survivin
or pSTAT3 after UV irradiation. When wild-type mice were
treated with indomethacin, survivin levels were also
reduced but could be restored by treatment with PGE2 or
butaprost, the EP2 agonist. Additionally, inhibition of
EGFR activity blocked the effect of butaprost, indicating
that COX-2 synthesis of PGE2 regulates survivin expres-
sion in keratinocytes, in part, through an EP2-mediated
EGFR/STAT3 pathway. This in turn suggests that EP2/
survivin may be an efficacious target for chemoprevention
or therapy of skin cancer [60]. However, as discussed
earlier, the observation by Brouxhon et al. [46] that while
EP2 null mice develop fewer tumors than wild-type mice,
the tumors that do arise are more aggressive.
The EP2 receptor has also been implicated in the
progression of epidermal lesions from dysplastic to SCCs.
Brouxhon et al. [61] showed a sequential loss of E-
cadherin-mediated cell-cell contact with tumor progression
due to decreased E-cadherin levels. Use of EP2 agonists or
EP2 deletion indicated that EP2 mediates the mobilization
of E-cadherin for proteosomal degradation [61], although
the molecular mechanisms by which this occurs are
currently unknown.
Thus a clear picture is emerging that EP2 receptor
activation results in altered keratinocyte behavior that is
associated with malignancy, including survival, prolifera-
tion, angiogenesis and invasion. Similar findings with other
epithelial tissues suggest that this may be a ubiquitous
phenomenon for most, if not all, epithelial tissues. For
example, in the APC
Δ716 mouse model of intestinal polyps,
EP2 receptor activation results in induction of vascular
epithelial growth factor (VEGF) that causes tumor angio-
genesis [62]. Similarly, in mouse mammary tumor cells,
activation of the EP2 receptor by PGE2 induced VEGF
though a cAMP/PKA pathway that did not involve hypoxia
inducible factor (HIF)-1α, MAPK or PI3K/AKT [63]. The
EP2 receptor also stimulates proliferation of colon cancer
cells, albeit through pathways involving PI3K/AKT and β-
Fig. 3 EP2 signaling in keratinocytes. Ligand activation of the EP2
receptor causes the activation of at least several signaling pathways.
Receptor activation results in conformational changes causing a loss
of GDP from the α subunit of the Gs protein and binding of GTP,
which leads to activation of membrane bound adenylate cyclase (AC).
Activation of AC results in the conversion of adenosine triphosphate
into cyclic adenosine monophosphate (cAMP), which activates protein
kinase A (PKA). PKA is responsible for activating, via phosphoryla-
tion, the transcription factor CREB and the signaling factor ERK1/2.
Activation of EP2 can also lead to the formation of a β-arrestin1-Src
complex, with subsequent activation of the epidermal growth factor
receptor (EGFR). Activation of EGFR causes activation of both the
ERK1/2 (MAPK) and AKT pathways. The activation of downstream
components of these 3 pathways leads to increased survival (p-Bad),
increased proliferation (Cyclin D1), angiogenesis (VEGF) and inflam-
mation (COX-2), all of which contribute to tumorigenesis
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mediates proliferation in many cells; the confounder is that
the signaling pathways and mechanisms are cell-type
dependent. Future work may show that at least some of
these pathways are interconnected, which would provide a
more universal picture of the mechanism of action of the
EP2 receptor.
4 The EP3 receptor
Of the four EP receptors, EP3 is the most complex and also
the least studied receptor. EP3 differs from the other EP
receptors in that multiple variants can be generated by
alternative splicing of the C-terminal tail. In mouse, there
are three splice isoforms of EP3, α, β, and γ, containing C-
terminal tails of 26–30 amino acids that do not have
structural motifs or hydrophobic features in common. The
α isoform has a hydrophilic tail while the beta isoform has
a hydrophobic tail. Although they both have the same
ligand binding properties, because of differences in their C-
terminal tails the different isoforms couple to different G
proteins, resulting in differences in signaling [19, 64].
The EP3 and EP4 receptor have binding constants in the
sub-nanomolar-range, with EP3 having the highest affinity
for PGE2 of all the EP receptors. This suggests that EP3
likely has a maintenance function in the epidermis where it
would respond primarily to COX-1 elicited PGE2 due to the
lack of expression of COX-2 in naive skin. However,
determining the function of EP3 is complicated by the fact
that the splice variants encode different functional proteins,
which elicit numerous intracellular signaling pathways.
Depending on the cell type, EP3 has been shown to inhibit
adenylate cyclase, stimulate adenylate cyclase, activate
PLC, activate nitric-oxide-cyclic GMP pathways and
activate Rho-dependent pathways [65].
Although human keratinocytes express all four EP
receptors, the level of expression of EP2 and EP3 is
considerably higher than expression of EP1 or EP4 [66]. In
naive mouse skin, however, the EP3 receptor has been
reported to be expressed at moderate levels throughout the
epidermis [26], although Tober et al. [27] found that, unlike
the EP1 or EP2 receptor, EP3 localized to the proliferative
basal compartment of the epidermis. This was recently
corroborated by Honda et al. [67], who found colocalization
with keratin 5. EP3 receptor expression was reported to be
localized to the cytoplasm and perinuclear region of
keratinocytes, although it was localized to plasma mem-
brane in dermal sebocytes [27]. Perinuclear localization of
EP3 has been noted in other tissues as well, including
human kidney, porcine brain endothelial cells, and rat liver
[68], suggesting the ubiquitous nature of this localization.
In chronically UV-irradiated skin of SKH-1 mice, EP3
receptor expression was undetectable by immunohisto-
chemistry [26], although in another study using a single
exposure to UV, EP3 receptor expression was observed
throughout all layers of the epidermis by 48 h [27]. The
reason for the conflicting data on the protein expression of
EP3 is unknown. Interestingly, inhibition of the EP1 receptor
with ONO-8713 prevented UV-induced EP3 expression in
the suprabasal keratinocytes, suggesting a regulatory inter-
action between the EP1 and EP3 receptors [27].
Our laboratory measured EP3 mRNA levels in FVB
mice and found that they were upregulated by both single
and multiple treatments with TPA (unpublished data).
However, Tober et al. [27] found that acute UV exposure
reduced expression of EP3γ and EP3β, compared to
unirradiated skin, although in chronically irradiated skin
only EP3β was significantly downregulated. With regard to
human keratinocytes, Konger et al. [40] showed that three
splice variants, EP3A1, EP3C, and EP3D mRNAs, were
expressed in primary cultures. Analysis of protein expres-
sion by Western blotting (the three isoforms have similar
molecular weights) showed that expression of the EP3
receptor was not affected by the extent of confluency or
state of calcium-induced differentiation. Immunohistochem-
ical localization in intact human skin showed positive
staining throughout the epidermis, with staining most
prominent in the basal layer where cytoplasmic, plasma
membrane, and perinuclear staining patterns were observed.
It was postulated that the perinuclear/nuclear localization is
related to an autocrine function of EP3 because cyclo-
oxygenases and microsomal PGE synthase are also local-
ized there. On the other hand, the plasma membrane
localization is consistent with a role for EP3 in responding
to paracrine signaling [40]. Neumann et al. [23] reported
that EP3 protein was elevated by 20% in their COX-2
transgenic mice. Overall, these studies indicate the induc-
ible nature of this receptor.
In tumors arising from chronic UV exposure, very little
expression of EP3 protein or mRNA was seen by Lee et al.
[26] in either benign papillomas or SCC. Tober et al. [27]
reported that in tumors from chronically UV-irradiated
mice, EP3α and β were significantly repressed while EP+
remained unchanged. Neumann et al. [23] also reported that
in papillomas from a two-stage experiment in NMRI mice
that the mRNA for EP3 (splice variants were not measured)
appeared to decrease, although this was not rigorously
evaluated. It is difficult to compare the results of the above
studies because different tumor-inducing protocols were
used and only one study [27] assessed expression at the
isoform level. However, there appears to be some, if
variable, decrease in EP3 expression in murine skin tumors.
In an early study focused on understanding the contri-
bution of each EP receptor to the proliferation of human
keratinocytes, Konger et al. [45] reported that growth
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mediated responses while activation of EP3 by sulprostone,
which lacks EP2 or EP4 agonist activity, inhibited
proliferation. There was no measurable effect of EP3
activation on cAMP levels, indicating that growth inhibi-
tion was independent of adenylate cyclase pathway signal-
ing. The growth inhibitory affect of EP3 is not restricted to
the epidermis as this has been observed in colonic
epithelium as well, and EP3 expression is downregulated
in colon cancer [69]. A subsequent study by Konger et al.
[40] explored the relationship between the lipid second
messengers DAG and ceramide, which are known to inhibit
growth, and the activity of EP3. They found that the EP3
agonist sulprostone, which inhibits growth, quickly induces
DAG and ceramide production and this was completely
blocked by an antagonist of the EP1-3 receptors. Sulpro-
stone was also shown to induce the cell-cycle inhibitory
protein p21
WAF1 [40].
The growth-promoting activity of EP2 and growth
inhibitory activity of EP3 suggests that their overall effect
on keratinocyte proliferation depends on ligand concentra-
tion as well as the level of receptor expression. As
discussed by Konger et al. [40], the low-affinity EP4
receptor requires a 100-fold greater concentration of PGE2
for maximal activation than the EP3 receptor. Stimuli that
induce COX-2 and thus raise PGE2 levels, or exogenous
PGE2, have been reported to increase keratinocyte prolif-
eration above that of basal conditions where PGE2 levels
are low [9, 49]. Additionally, stimuli such as tumor
promoters or wounding can increase EP2 expression, thus
shifting the homeostatic balance between proliferation and
differentiation that occurs in the normal epidermis, to a
more proliferative state. This may be the reason for our
finding that the EP3 receptor does not appear to play a
significant role in skin tumor development. Our laboratory
subjected EP3 null mice to the two-stage DMBA/TPA
protocol and observed no differences in either tumor
multiplicity or tumor incidence, compared to wild-type
mice. The tumor size distribution was also almost the same
as wild-type mice [24]. Similar studies on EP3 knockout
mice were performed by Shoji et al. [70] in which they
observed an enhanced latency in skin tumor development in
the EP3 null mice early in the experiment, although by the
end of the study tumor multiplicity and incidence were
identical. Interestingly, they found no SCC in the EP3 null
mice while ∼12% of the wild-type mice developed SCCs
[70]. The overall lack of a role for the EP3 receptor in skin
cancer is consistent with similar observations in other
epithelial cancers, including colon and breast [71, 72].
A possible role for EP3 in cutaneous inflammation has
also been studied, based on the known pro-inflammatory
effects of PGE2, however, the outcomes of these studies are
not consistent. A study by Goulet et al. [73] showed that
EP3 mediated the pro-inflammatory action of PGE2,
measured by the edema response to topical arachidonic
acid. Using mice that were deficient in each of the EP
receptors, only the absence of the EP3 receptor resulted in a
significant reduction in edema and vascular permeability
compared to wild-type mice [73]. As discussed by Goulet et
al. [73] there are a number of reasons for expecting EP3 to
mediate edema. The second messenger systems to which
EP3 is linked would be expected to result in vasoconstric-
tion instead of vasodilatation and this was previously
observed by others [74]. Other studies showed that
pharmacological agents that preferentially activate EP3
receptors potentiated bradykinin-induced inflammation in
rabbit skin [75]. Additionally, in atopic dermatitis, PGE2
promotes the innervation of skin lesions through the
activation of the EP3 receptor in keratinocytes, which
subsequently induces neurotrophin-4. The signaling path-
way utilized in this case is the phosphoinositol-specific
PLC/PKCα/ERK pathway [76]. Thus, there are several
examples of a pro-inflammatory role for the EP3 receptor in
skin, although the signaling pathways utilized may depend
on the etiological agent and/or isoforms that are activated.
There are other studies, however, in which EP3 receptor
activation has anti-inflammatory activity. Using selective
EP receptor agonists, Ahluwalia and Perretti [77] reported
that EP3 has anti-inflammatory effects against edema
elicited by exogenous agents. Kanda et al. [66] analyzed
the contribution of each EP receptor to PGE2-induced
inhibition of NFκB activity and expression of the skin-
homing T cell chemokine CCL27. Antagonists for EP3 or
EP1/EP2 each partially blocked the PGE2-induced inhibi-
tion of CCL27, while together they completely blocked the
response [66]. In another study on the role of EP3 in
allergic skin inflammation in mice, use of an EP3 agonist,
but not agonists of the other EP receptors, reduced the
extent of edema and inflammatory cell infiltration. Micro-
array analysis of keratinocytes from mice treated with the
EP3 agonist ONO-AE-248 showed that expression of
neutrophil-recruiting chemokines, especially CXCL1 and
CXCL2, were suppressed, compared to control mice, which
correlated with reduced neutrophil infiltration. Additionally,
in cultured keratinocytes, the EP3 agonist suppressed
CXCL1 expression and production induced by TNFα,
indicating that EP3 is anti-inflammatory through altering
the expression of genes in keratinocytes that are responsible
for the dermal infiltration of inflammatory cells. Converse-
ly, a deficiency in EP3 expression enhanced the edema
associated with allergic inflammation in skin [67].
The anti-inflammatory effect of EP3 in allergic skin
reactions was postulated to be due to EP3 coupled with Gi
because the cAMP decrease mediated by Gi occurs at lower
agonist concentrations than Gs or Gq signaling [67]. In
general, Gi activation by the murine EP3 receptor isoforms
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There are, however, several novel associations of EP3 other
than in Gi/Gs signaling, although the extent to which this
occurs in epidermal cells has not been well studied [65]. In
CHO cells, activation of the three mouse EP3 isoforms
causes intracellular Ca
2+ mobilization through the Gβγ
subunit of the Gi protein. This may augment cAMP
synthesis resulting from activation of Gs by other receptors,
including EP2 [65]. This contributes to the complexity of
understanding the function of the EP3 isoforms.
The reason for the discrepancy between the various
studies on the role of the EP3 receptor in inflammation is
not clear although differences in models (pharmacological
vs. genetic), isoform expression and methods of eliciting
inflammation likely play a role. The lack of a role for the
EP3 receptor in skin tumorigenesis [24, 70], in which
inflammation is generally a driving force, suggests that EP3
is not strongly enough anti-inflammatory or anti-
tumorigenic to counteract the pro-tumorigenic activity of
the other EP receptors.
5 The EP4 receptor
The EP4 receptor has several structurally unique features
that suggest that its activation may result in distinctive
biological responses. This receptor has a much longer
cytoplasmic tail and has an insertion of 25 amino acids in
the third intracellular loop, both of which are involved in
coupling to G proteins. Additionally, unlike the other EP
receptors, EP4 is rapidly internalized in response to PGE2
[22]. The deduced transcription initiation site contains
motifs usually associated with activation by proinflamma-
tory cytokines such as CCAAT boxes, Sp1, and AP-2 [78].
Understanding the mechanisms and outcomes of EP4
activation are thus of interest in a number of tissues,
including skin, and physiological processes.
In localization studies on the EP receptors in mouse skin,
although Lee et al. [26] found that the EP4 receptor was
virtually undetectable by immunohistochemistry, Tober et
al. [27] found EP4 protein expression in the majority of
murine epidermal keratinocytes and dermal leukocytes in
naive skin. Neumann et al. [23] also found low but
detectable EP4 protein by Western blotting. In UV-
irradiated skin EP4 protein expression was reported to be
undetectable in one report [26], but Tober et al. [27] found
acute and chronic UV induced relocalization to the plasma
membrane in the more highly differentiated cells of the
stratum granulosum, although diffuse cytoplasmic staining
was observed throughout the rest of the epidermis.
With regard to a role for EP4 in NMSC, in human SCCs,
EP4 mRNA was reported to be significantly upregulated,
although it was downregulated in BCCs, compared to
normal skin. In murine skin tumors resulting from chronic
UVexposure, Lee et al. [26] also observed increased levels
of EP4 protein in both papillomas and SCC, although the
mRNA levels were not significantly increased. This was
corroborated by Tober et al. [27] in UV-elicited murine
tumors and by Neumann et al. [23] in papillomas from a
DMBA/TPA protocol. When our laboratory evaluated EP
receptor expression in mice, we found that both in TPA-
treated skin and in papillomas and SCCs, EP4 mRNA was
reduced, compared to wild-type skin [79, 80]. It is not clear
at this time whether the differences in EP4 mRNA
expression reported by others [23, 27] and our laboratory
[79, 80] are due to differential activities of UVand TPA. As
described in Section 3 above, the Langenbach laboratory
has been interested in elucidating the involvement of
specific EP receptors in UV-induced apoptosis and tumor
development [54–56]. They found that both EP2 and EP4
were responsible for the anti-apoptotic effects of PGE2 via
regulating pBad levels, following UV irradiation [56].
However, differences were seen in other downstream
events. EP2 receptor activation was found to upregulate
survivin expression via an EGFR/STAT3 pathway that
likely contributes to, or is responsible for, the anti-apoptotic
activity of EP2. Activation of EP4, however, did not
increase STAT3 activation or survivin levels [60]. Although
the mechanism/pathway by which EP4 exerts its anti-
apoptotic activity has not yet been elucidated in keratino-
cytes, the EP4 receptor has strong anti-apoptotic effects in
glomerular epithelial cells via activation of AKT [81]; it is
likely that the AKT survival pathway is operative in the
epidermis as well [26].
Studies in other organ systems led to the suggestion that
EP4 may actively contribute to skin cancer. Mutoh et al.
[82] reported that EP4 null mice treated with the carcinogen
azoxymethane reduced the development of aberrant crypt
foci to 56% of the wild-type level. Additionally, adminis-
tration of the EP4 receptor antagonist ONO-AE2-227 also
reduced formation of aberrant crypts as well as intestinal
polyps in the Min mouse [82]. EP4 receptor antagonists
have also been used to show that EP4 inhibits experimental
metastasis of murine mammary tumor cells [83].
Based on these reports, our laboratory has been
investigating the effect of EP4 overexpression on murine
skin tumor development. Transgenic mice that overexpress
EP4 under the control of the BK5 promoter (BK5.EP4
mice) were generated on the FVB background. At the
macroscopic level, the skins of these mice are essentially
identical to wild-type skin, although the hair cycles are
slightly different. When subjected to the two-stage DMBA/
TPA protocol, the BK5.EP4 mice develop many more
tumors than wild-type mice. Additionally most of the
tumors in the transgenic mice were SCC while in wild-
type mice the majority were benign papillomas. This
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EP1 transgenic mice [30] except that there was a greater
latency to tumor development. Because TPA treatment of
the BK5.EP4 and wild-type mice did not produce pro-
nounced differences in epidermal proliferation or apoptosis,
which are events usually associated with tumor promotion,
the effect of DMBA alone was investigated. Using a single
application of DMBA, a significant number of SCCs
developed in the BK5.EP4 mice but not wild-type mice.
Macroscopically, it was apparent that DMBA caused
sloughing of the epidermis of the transgenic but not wild-
type mice, and this was associated with an increase in
apoptosis. This was followed by a significant increase in
keratinocyte proliferation in the transgenic skin as well as a
robust angiogenic response, consistent with regenerative
hyperplasia. Studies on expression of enzymes involved in
metabolizing DMBA, CYP1A1 and CYP1B1, and stem cell
numbers (CD34 and α6 integrin positive cells) showed no
difference in these parameters. Additionally, ongoing
studies are showing that UV exposure also produces a
sloughing and angiogenic response in the transgenic, but
not wild-type, mice (unpublished data), suggesting that the
EP4 transgenic epidermis has a much lower apoptosis
threshold than wild-type mice. The basis for this is
currently under study. It is clear, however, that the EP4
receptor contributes to skin tumor development and appears
to be particularly important in the development of malig-
nant (SCC) rather than benign (papillomas) tumors [79, 80]
(and unpublished data).
The involvement of EP4 in UV-induced dermal inflam-
mation has also been studied using genetic and pharmaco-
logical approaches. Kabashima et al. [84] reported that
edema, inflammatory cell infiltration, and local blood flow
were reduced in both EP2 and EP4 null mice. Interestingly,
EP4 mediates an anti-inflammatory response in macro-
phages and does so through an EP4 (but not EP2)
interacting protein, EP4 receptor-associated protein
(EPRAP); the complex also interacts with NFκB[ 85].
Whether EPRAP is expressed in other cell types is
unknown. Recently, however, EP4 receptor activity in skin
was shown to mediate UV-induced systemic immunosup-
pression; EP4 antagonist treatment downregulated UV-
induced expression of receptor-activator-of-NFκB-ligand
in keratinocytes which elevates the number of regulatory
T cells [86].
It is of interest that of the events elicited by the EP2 and
EP4 receptors, some are the same while others are signifi-
cantly different. Both EP2 and EP4 have anti-apoptotic
activity against UV exposure [56] and overexpression of
each promotes skin tumor development [44, 79, 80]. In
human adipocytes and breast cancer cells, both EP2 and EP4
upregulate aromatase expression and do so through activa-
tion of the cAMP/PKA/CREB pathway [87]. However, EP2,
but not EP4, induces survivin in keratinocytes [60]. It is
likely that the similarities between EP2 and EP4 are due to
both receptors signaling via the cAMP-PKA pathway; the
differences are likely due to observations that EP4, but not
EP2, also activates the PI3K pathway that can lead to AKT
activation as well as ERK activation (Fig. 4)[ 88]. It has also
been shown that under equal expression levels, EP4
activation results in significantly less cAMP production than
EP2 activation [51]. Both the EP2 and EP4 receptors couple
to the stimulatory guanine tripeptide Gαs and via this
linkage activate adenylate cyclase. The weaker stimulation
of cAMP production by the EP4 receptor could also be due
to its rapid desensitization, but signaling via PI3K is robust,
suggesting that other factors are involved [22]. In this regard,
EP4, but not EP2, can couple with a pertussis toxin-sensitive
inhibitory G-protein (Gαi) that leads to activation of PI3K
signaling [89]. Furthermore, EP4 activation of PI3K results
in inhibition of PKA, which is activated by EP2. Addition-
ally, although the transcription factor CREB is phosphory-
lated on serine 133 following either EP2 or EP4 activation,
this phosphorylation is mediated through different signaling
pathways, i.e., via PKA for EP2 and via AKT for EP4 [52].
The extent to which these signaling pathways are differen-
tially activated will also depend on the level of PGE2
because the affinity of EP2 for PGE2 is considerably lower
than that of EP4 [65]. Clearly, the biological outcomes of
EP2 and EP4 activation are very context dependent,
involving levels of expression of the EP (and other
interacting) receptors, ligand, as well as cross-talk among
the EP and other receptors.
As described in Section 3, we showed that the EP2
receptor induces COX-2 in murine keratinocytes in a cAMP
Fig. 4 EP4 signaling in keratinocytes. Similar to the EP2 receptor,
ligand activation of EP4 also leads to activation of adenylate cyclase
(AC) with subsequent formation of cAMP and activation of the
transcription factor CREB, although the extent of cAMP formation is
significantly less than that resulting from EP2 activation. Although the
mechanisms are not understood, activation of the EP4 receptor causes
activation of the PI3K and AKT pathway. Thus, the biological
outcomes of EP2 vs. EP4 activation are somewhat different, although
both contribute to the development of skin cancer
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activation could also induce COX-2, in this case through a
PI3K/AKT pathway leading to an inhibitory phosphoryla-
tion of GSK-3α which is also inhibited when PKA is
activated, followed by translocation of cytosolic β-catenin
into the nucleus. In the nucleus, β-catenin interacts with the
Tcf/Lef family of transcription factors that results in
induction of COX-2. Thus, both EP2 and EP4 signaling
induce COX-2, although different mechanisms are involved
[22]; as has been previously mentioned, it is possible that
the constitutive upregulation of COX-2 observed in many
epithelial tumors is due to a positive feedback loop
involving COX-2 and the EP2/EP4 receptors [49, 56].
PI3K activation by EP4 also leads to the phosphorylation
(activation) of ERK1/2, which induces early growth
response factor-1 (EGR-1). EGR-1 regulates at least several
genes involved in proliferation and inflammation, including
TNF-α, PGE2 synthase and cyclin D1, supporting a role for
the EP4 receptor in neoplastic processes [88].
Interestingly, EP4 receptor expression was shown to be
downregulated by a number of cancer chemopreventive
agents, including troglitazone, sulindac sulfide and indo-
methacin in human glioblastoma cell lines [90]. In
melanoma cells, the anti-carcinogenic alkaloid berberine
was reported to repress expression of EP2, EP4, and COX-
2 through inhibition of NFkB activation [91]. These recent
studies indicate that new mechanisms of action may be
ascribed to a number of chemopreventive agents. Future
studies in this area may identify additional agents that are
effective in either repressing EP4 expression or blocking its
activity. Given the pro-tumorigenic role for EP4, this could
offer new approaches to the prevention of NMSC.
6 Conclusions
In this review, we provide evidence from several laborato-
ries that the EP1, EP2, and EP4 receptors mediate the tumor
promoting activity of PGE2 in NMSC. This information
offers possibilities for preventing NMSC development and
for potentially intervening in the progression of these
tumors. Elucidation of the signaling pathways activated by
these receptors also illuminates possible targets for preven-
tion/intervention. Further studies are needed to validate this
approach because these signaling pathways are utilized in
normal keratinocyte proliferation, differentiation and cell-
cell interactions. However, it has been well-demonstrated
that inhibiting PI3K/AKT, MAPK or c-Src signaling path-
ways early in epithelial neoplasia results in reduced
keratinocyte proliferation and survival, leading to decreased
tumor formation [92].
The interaction of the EP1, EP2 and EP4 receptors with
EGFR raises some interesting questions and options, and is
very significant because EGFR-mediated signaling has also
been implicated in proliferation, survival, invasion, angiogen-
esis and metastases, all of which are associated with tumor
development [16]. Because of similarities between EGFR
and other growth factor receptor tyrosine kinases (RTKs),
one or more of the EP receptors may interact with other
RTKs. While this muddies our understanding of the path-
ways by which the EP receptors carry out their function, it
also supports the hypothesis that tumor promotion is
characterized by, and is due to, a chronic state of aberrant
signaling through numerous pathways [10, 49].
The approaches taken so far in inhibiting EP receptor
activity have lacked cell-type specificity, i.e., whole animal
knockouts ortreatment ofskinwithinhibitorshavebeenused.
Because thisislikelytoaffectother cell types suchasstromal,
immune, or inflammatory cells, it confounds our understand-
ing of the role of the EP receptors in keratinocytes, in terms of
both normal function and NMSC development. Studies using
targeted ablation in vivo are needed to definitively establish
the function of each EP receptor in keratinocyte behavior.
Additional studies are also needed on understanding how
the EP receptors are regulated. As previously described, tumor
promoting agents such as phorbol esters and UV can
upregulate several of the EP receptors. Elucidating the
signaling pathways and transcription factors involved in this
upregulation would be potentially useful in designing
approaches to regulating keratinocyte behavior and in under-
standing how important the level of expression of each EP
receptoristonormalandpathologicalkeratinocytephysiology.
The significance of elucidating the regulation and function
of the EP receptors in NMSC lies in the recognition that
NMSC is the most common cancer affecting humans—
NMSC accounts for 40% of all newly diagnosed cancers
andtheincidenceisrising[93]. New strategies and targets are
needed to prevent or intervene in NMSC; inhibition of the
EP receptors has great potential as an effective new approach
to prevention of NMSC as well as other epithelial cancers.
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